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Review Article 
Gastritis with Distinctive Histopathology (Non-Helicobacter Pylori Gastritis)
Kunihiko MURASE
Second Department of Internal Medicine, Nagasaki University School of Medicine
 Distinctive gastritis refers to gastritis with distinctive 
histological and endoscopic features, including the presence of 
granulomas, the increased number of intraepithelial lympho-
cytes, eosinophilic infiltration, thickening of the subepithelial 
collagen band, and foveolar hyperplasia. Several forms of 
distinctive gasatritis are reviewed in this issue, since under-
standing of its pathogenesis and the accurate diagnosis are 
implicated in clinical prognostic biomarkers and lead to a 
new therapeutic approach. 
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Introduction 
 Helicobacter pylori (H. pylori) and nonsteroidal 
antiinflammatory drugs (NSAIDs) are the most common 
causes of gastritis (1, 2). Many studies have shown 
that successful eradication of H. pylori markedly re-
duces the rate of peptic ulcer relapse, together with a low 
recurrence rate of H. Pylori infection (3-5). Only a few 
patients with H. pylori infection treated succesfully de-
velop reflux esophagitis and other symptoms without 
reinfection with H. pylori (6-8). 
 A distinctive form of gastritis has recently been de-
scribed in association with H. pylori infection (9-11). A 
major problem in classifying gastritis is the simultaneous 
coexistence of two or more types of gastritis. A low 
frequency of H. pylori infection is reported in patients 
with inflammatory bowel disease (IBD) (12, 13), how-
ever, there is some evidence to suggest that Crohn's 
disease-associated gastritis are masked by H. pylori
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gastritis (10, 11). 
 Here I review several distinctive forms of gastritis to 
help clinicians to make the accurate diagnosis and to 
manage patients with non-H. pylori gastritis or those 
in whom H. pylori had been previously eradicated.
Granulomatous gastritis
 Granulomatous gastritis occurs in association with 
systemic granulomatous diseases such as tuberculosis 
(14), sarcoidosis (15), neoplastic disease (16), and idio-
pathic granulomatous gastritis (17), where the most 
common cause is Crohn's disease (18-20). 
 Crohn's disease is a chronic disease of unknown eti-
ology that can affect any part of the gastrointestinal 
tract, and is characterized by aphthoid ulceration, cob-
ble stoning, transmural chronic inflammation, and 
granuloma formation (18). In the proximal gastrointes-
tinal tract, the gastric antrum and the duodenum are 
most frequently affected, and the encountered lesions 
on endoscopic examination consist of aphthoid erosions, 
ulcers, thickening of folds, nodules, erythema and 
stenosis (21). It has recently been suggested that a bam-
boo joint-like appearance is a characteristic endoscopic 
finding of Crohn's disease, representating swollen lon-
gitudinal folds traversed by erosive fissures in Crohn's 
disease (Fig. 1-A), although its pathogenesis is un-
clear (22, 23). When upper gastrointestinal symptoms 
are present, the clinical course may progress in paral-
lel with activities in the ileum or the colon (19). 
 Chronic gastritis and duodenitis are common in pa-
tients with Crohn's disease; however, the majority of 
cases are not associated with H. pylori infection (12, 13). 
A few reports have stressed that previous use of 
sulphasalazine is associated with a reduced risk of in-
fection with H. pylori in patients with Crohn's disease 
(24, 25). Epithelioid granuloma is considered a histological 
hallmark of Crohn's disease (Fig. 1-B), but such 
granulomas are only found in 2-5% of patients with 
gastric Crohn's disease (18, 19). Recently, focal active 
gastritis is recognized as a form of inflammation that
seems to be typical of gastric Crohn's disease (Fig. 1-C) 
(26-28), which resembles focal cryptitis observed in 
the colonic mucosa. In our study, focal active gastritis 
was detected in 28% of patients with known Crohn's 
disease. The prevalence rate increased to 54% in H. py-
lori-negative patients with Crohn's disease, but it was 
not found in patients with ulcerative colitis or non-IBD 
patients (28). Thus, we believe that gastric involve-
ment in Crohn's disease is not rare as previously 
thought. H. pylori-associated gastritis may mask focal 
active gastritis in patients with Crohn's disease, which 
may be identified a successful eradication of H. pylori 
(11). 
 Oberhuber et al (26) reported a high incidence of 
focal active gastritis in Crohn's disease and described 
accumulation of CD68-positive macrophages in this le-
sion. In our study (28), mast cells accumulated in the 
peripheral area of focal active gastritis, whereas macro-
phages accumulated in the center of the lesion. Such 
accumulation of mast cells and macrophages might be 
associated with the pathogenesis of focal active gastri-
tis in patients with Crohn's disease.
Lymphocytic gastritis
 Lymphocytic gastritis is a new entity described in 
1985 by Haot et al (29), and is histopathologically 
characterized by accumulation of intraepithelial lym-
phocytes on the surface and foveolar epithelium. 
Endoscopically, enlarged folds bearing small nodular 
elevations surmounted by erosions are found particu-
larly in the corpus and the fundus. 
 Lymphocytic gastritis is associated with celiac dis-
ease (30, 31), H. pylori gastritis (31, 32), varioliform 
gastritis (33, 34), mucosal associated lymphoid tissue 
(MALT) lymphoma (35, 36), and gastric cancer (35). 
This suggests that the lymphocytic gastritis may be 
associated with an increased risk of developing lym-
phoma or carcinoma. We have a case of lymphocytic 
gastritis associated with signet ring cell carcinoma of 
the stomach (Fig. 2). 
 Patients with lymphocytic gastritis show infiltrations 
of neutrophils and eosinophils and mononuclear in-
flammatory cells, and foveolar hyperplasia in the corpus 
mucosa. The diagnostic threshold for accumulation of in 
flammatory cells in lymphocytic gastritis is usually taken 
as > 25 intraepithelial lymphocytes per 100 epithelial 
cells (37). Immunohistochemical studies have shown 
that the intraepithelial lymphocytes in lymphocytic 
gastritis are exclusively CD3 positive T cells, and ap-
proximately 80% of them are CD8 positive (37, 38). 
Intraepithelial lymphocytes are likely to participate in
regulation of mucosal inflammatory reaction (39, 40). 
 There are smaller numbers of H. pylori in lymphocytic 
gastritis than in H. pylori-positive patients who did not 
have lymphocytic gastritis (31, 41). Few studies have 
indicated that eradication of H. pylori or treatment with 
histamine 2 (H2) receptor antagonists or proton pump 
inhibitors in these patients results in a significant im-
provement in intraepithelial lymphocytic infiltration 
(42-45), although lymphocytic gastritis may, in part, 
represent a specific immune response to H. pylori (46, 
47).
Collagenous gastritis
 Collagenous gastritis is an extremely rare disorder 
with only seven case reports in the English literature, 
and little is known about its etiopathogenesis and 
natural history (48-54). Nodular and erythematous le-
sions in the gastric corpus are common endoscopic 
findings. Biopsy specimens show a thick subepithelial 
band, and thickening of the collagen plate of more than 
10 'Um has been proposed as a threshold criterion for 
the histological diagnosis of collagenous gastritis (53). 
Recently its associations with lymphocytic gastritis, 
sprue, and lymphocytic colitis as well as collagenous 
and lymphocytic colitis suggest a common pathogene-
sis that may empirically include collagenous gastritis 
in the same disease spectrum (50, 55). Ultrastructural 
examination of the gastric biopsy specimens shows a 
patchy subepithelial band of collagen fibers. Capillaries, 
lymphocytes, eosinophils, mast cells, and fibroblasts 
were seen entrapped in this band (53). Mast cells can 
induce migration and proliferation of fibroblasts and 
can also stimulate collagen synthesis. Mast cells en-
trapped in the collagen band and located in the lamina 
propria also showed evidence of degranulation (53, 54). 
 Immunohistochemical studies have shown signs of 
the local immune activation in all biopsy specimens, 
including overexpression of HLA-DR by epithelial 
cells, increased numbers of CD3-positive intraepithelial 
lymphocytes, and CD25-positive cells in the lamina 
propria (53, 54). These findings suggest that the 
histopathological lesions of collagenous gastritis may 
be mediated by a local immune process.
Eosinophilic gastritis
 Eosinophilic gastritis is defined as eosinophilic infiltra-
tion into the gastric wall with no evidence of parasitic or 
extraintestinal disease (56). Peripheral blood eosinophilia 
is often present, but some patients do not have this
Fig. 2 Lymphocytic gastritis; Numerous lymphocytes in the 
epithelium. Magnification, X200.
Fig. 1 Crohn's disease. A: Gastroendoscopy showing bamboo 
joint-like appearance with swollen longitudinal folds. B: 
Noncaseous granuloma with giant cells. Magnification, x 100 
C: Focal infiltration of polymorphs and mononuclear inflam-
matory cells in the foveola or gastric glands. Magnification, 
X 200.
Fig. 3 Eosinophilic gastritis. Gastroendoscopy showing multi-
ple gastric ulcers (A). Note the eosinophils particularly be-
neath the luminal epithelium (B) and sometimes within the 
epithelium and foveola (C). Magnification, X 100.
finding. A portion of patients develop symptoms fol-
lowing ingestion of specific food, suggesting that food 
allergy plays a role in the pathogenesis of eosinophilic 
gastritis (57). Eosinophilic infiltration into the stom-
ach occurs commonly in a variety of different inflamma-
tory conditions, including collagen disease (58), parasitic 
infection (59), and drug allergy such as interferon (60). 
 The clinical manifestations of eosinophilic gastritis 
depend upon the layers of stomach involved. The in-
volvement of a predominantly mucosal layer with ul-
cers tends to lead malabsorption, anemia and protein 
loss from gut (61) (Fig. 3-A). When the muscle layers 
are predominantly involved, the condition may be con-
fused with malignancy because it often causes the gas-
tric outlet obstruction (62, 63), in addition, the serosal 
involvement is frequently accompanied by eosinophilic 
ascites (64). Gastric antral biopsies are more productive, 
and eosinophils may be found prominently beneath the 
luminal epithelium or sometimes within the foveolum 
(Fig. 3-B, C). 
 Eosinophilic gastritis usually responds to corticosteroid, 
H2 receptor antagonists, and proton pump inhibitor 
therapy (58, 61), although cases resistant to these 
therapies (64, 65) or those with spontaneous resolu-
tion have been reported (66).
Hyperplastic gastropathies
 Hyperplastic gastropathy can be divided into the two 
main categories, Menetrie's disease and hyperplastic 
hypersecretory gastropathy. Patients with Menetrie's dis-
ease have giant gastric folds and hypoproteinemia, on the 
endoscopic examination, large gastric folds (> 10 mm in 
diameter) are found, which correspond to the echogenic 
thickening of the mucosal layer with or without cystic 
components on ultrasonography. Histopathologically, 
these folds represent the increased epithelial cell mass 
mainly consisting of mucous cells presenting elongated 
and sometimes cystically dilated foveola without parie-
tal cell hyperplasia, and mildly infiltrated inflamma-
tory cells (67). The cause of this disease is unknown, 
although various factors such as autoimmune, allergic, 
neoplastic, and infective (primarily cytomegalovirus and 
occasionally H. pylori, herpes simplex and mycoplasma) 
mechanisms have been proposed (68-71). Lymphocytic 
gastritis may share a common pathogenesis with 
Menetrier's disease (72). Menetrier's disease is associ-
ated with H. pylori in more than 90% of patients (69), 
and it is thought to be a special form of H. pylori gas-
tritis in these patients. 
 In hypertrophic hypersecretory gastropathy, the parietal 
cells rather than the foveolar cells proliferate to form the
enlarged folds (70). Some patients with hypertrophic 
hypersecretory gastropathy are ultimately confirmed to 
have Zollinger-Ellison syndrome. 
 It has been reported that eradication of H. pylori, or 
the use of proton pump inhibitors or antibiotic therapy 
improves fold width, foveolar length, and inflammatory 
infiltrates in patients with hyperplastic gastropathy 
(71-77). Increased productions of interleukin-1 lfl and 
hepatocyte growth factor caused by H. pylori infection 
may contribute to the fold thickening of the stomach 
by stimulating epithelial cell proliferation and foveolar 
hyperplasia in patients with enlarged fold gastritis (78).
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